0001209191-20-048173.txt : 20200824 0001209191-20-048173.hdr.sgml : 20200824 20200824203705 ACCESSION NUMBER: 0001209191-20-048173 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200820 FILED AS OF DATE: 20200824 DATE AS OF CHANGE: 20200824 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Krognes Steve E. CENTRAL INDEX KEY: 0001666236 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 201129220 MAIL ADDRESS: STREET 1: 863 MITTEN ROAD, SUITE 102 CITY: BURLINGAME STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-20 0 0001714899 Denali Therapeutics Inc. DNLI 0001666236 Krognes Steve E. C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 CFO and Treasurer Common Stock 2020-08-20 4 M 0 5643 A 1008465 I See footnote Common Stock 2020-08-21 4 F 0 1954 32.87 D 1006511 I See footnote Common Stock 3666 D Restricted Stock Units 2020-08-20 4 M 0 5643 0.00 D Common Stock 5643 0 D Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.835 to $32.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. /s/ Tyler Nielsen, by power of attorney 2020-08-24